Comparative trial of sulphadiazine-trimethoprim (co-trimazine), co-trimoxazole and sulphamethizole in the treatment of uncomplicated urinary tract infections.
A combination of sulphadiazine and trimethoprim (co-trimazine) has been developed specifically for the management of urinary tract infections. The pharmacokinetics of co-trimazine make it possible to use lower doses of both the sulphonamide and trimethoprim than in co-trimoxazole, while maintaining clinical efficacy. One hundred and twenty women with a urinary tract infection were randomly allocated to a five-day course of treatment with either co-trimazine (sulphadiazine 410 mg and trimethoprim 90 mg 12-hourly), co-trimoxazole (sulphamethoxazole 800 mg and trimethoprim 160 mg 12-hourly) or sulphamethizole (1 g 8-hourly). The respective cure rates were 95, 98 and 90 percent. No serious side effects of therapy were encountered. Co-trimazine proved to be an effective antibacterial combination for the treatment of uncomplicated urinary tract infections.
D000328:Adult; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D013411:Sulfadiazine / Q000627:therapeutic use*; D013419:Sulfamethizole / Q000627:therapeutic use*; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D013432:Sulfathiazoles / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014552:Urinary Tract Infections / Q000188:drug therapy*; D000096926:Benzenesulfonamides
D004338:Drug Combinations; D013411:Sulfadiazine; D013419:Sulfamethizole; D013420:Sulfamethoxazole; D013432:Sulfathiazoles; D014295:Trimethoprim; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; C024873:sulfadiazine, trimethoprim drug combination; D000096926:Benzenesulfonamides